WAVE
Who is this for?
Healthy and/or those with mild lung/liver damage alpha-1 antirypsin deficiency patients with a ZZ genotype
Study:
This study looks at the drug WVE-006. It aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics in single and multiple ascending doses of the investigational drug.